tirzepatide우선순위 낮음근거 검토기타
LITERATURE DETAIL · PMID 42395062
Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.
Impact of incretin therapies on biochemical and imaging outcomes in metabolic dysfunction-associated steatotic liver disease.
- 저자
- Nicole Ann Tesoro, Frederick Berro Rivera, Nathan Ross B Bantayan, John Vincent Magalong, Romaine Tomada, Maria Antonia Wong
- 저널
- American journal of preventive cardiology
- 공개일
- 2026 Aug
- 연구 유형
- 기타
- DOI
- 10.1016/j.ajpc.2026.101623
문헌 요약
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver condition. Incretin therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and emerging dual agonists, have shown promise in improving steatohepatitis. This study aims to evaluate the efficacy and safety of incretin therapies compared wi…
PV 검토 포인트
누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.